Navigation Links
Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
Date:6/18/2009

report 100% treatment success in the moderately infected ulcer study indicating that use of our product has the potential to address a very significant and rapidly growing unmet medical need."

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll has licensed its US marketing rights to its lead product, CollaRx GENTAMICIN SURGICAL IMPLANT to Baxter Healthcare, a division of Baxter International Inc (NYSE: BAX) The product is currently in phase 3 development in the US for the prevention of surgical site infections. It is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase 2 development. For more information, please visit www.innocollinc.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge
2. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
3. Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
4. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Innocoll Announces Closing of $30 Million Equity Financing Investment
6. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
7. Quest Diagnostics Announces Final Tender Offer Results
8. Precision Stability Storage Announces Upcoming Expansion
9. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
10. Wyeth Announces Holder Right to Surrender Convertible Debentures
11. Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... In her thought ... transports the reader to a not-so-distant future faced with an Ebola pandemic that is ... who overcomes personal tragedy to enter the world of counterterrorism, and who continues to ...
(Date:9/1/2015)... Boston, MA (PRWEB) , ... September 01, 2015 ... ... from top biopharmaceutical companies in the neuro and pain management space join prominent ... Joseph B. Martin Conference Center at Harvard Medical School in Boston. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based therapy ... at the Keck Graduate Institute and its collaborators. The discovery has the potential ... published online on August 27 by Scientific Reports, an open access research journal ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global ... chain risk management and resiliency practitioners with luminaries and thought leaders to advance ... be recognized for their innovations and performance excellence. At that time its principle ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... , , , 7.6.4 Long PCR , ... as desired with every temperature , command, enables a , ... , With Long PCR, this function can be used ... elongation. , , ...
... , , , , , ... set of conditions that can be applied to all PCR amplifications. For ... used, the annealing temperatures , of the PCRs can differ ... stringent annealing temperature is a prerequisite for reliable results , ...
... , , , , ... fragment using the PCR* are an everyday occurrence in the lab. For example, , ... which hinder, , or even prevent, further analyses (cycle ... of the PCR result. In such cases, PCR , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Using Gradient PCR to determine the optimum annealing temperature. 2
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... acetyl CoA carboxylase 2,or ACC2, appears to turn the ... in part why the animals can eat more and ... Medicine,researchers.,The report that appears online today in the Proceedings ... cells in these mice bred to lack ACC2," said ...
... University,of California, San Diego have invented a process ... of specialized cells being sought as possible,treatments for ... and Shu Chien, UCSD bioengineering professors, and Christopher,J. ... in a paper published in the February issue ...
... have discovered a way to overcome one of the ... kill normal cells in the,process of eradicating cancer cells.,In ... of the Proceedings of the,National Academy of Sciences (PNAS), ... into a specially designed,virus. The virus eradicated prostate cancer ...
Cached Biology News:Lack of enzyme turns fat cells into fat burners 2Priming embryonic stem cells to fulfill their promise 2Priming embryonic stem cells to fulfill their promise 3Columbia research lifts major hurdle to gene therapy for cancer 2